Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer

Li, Huifang; Gao, Jie; Feng, Yong

doi:10.3389/fonc.2022.1054086

Cited by 3 publications

(1 citation statement)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 Recent studies have shown that in addition to suppressing estrogen production and signaling, these agents can enhance the production of inflammatory cytokines, induce dysregulation of activities of circulating immune cells, including natural killer (NK) cells, 2 - 7 and boost immune responses. 8 - 10 By disrupting neuro-immune-endocrine (NIE) networks, 11 , 12 ET may contribute to fatigue, 13 sleep disruption, 14 and inflammation around the joints and muscles, 15 leading to impaired quality of life (QoL) and affecting treatment adherence. 16 As nonadherence to adjuvant ET is correlated with impaired cancer-specific survival, 17 proper management of these adverse effects is vital for improving the health outcomes of BC survivors.…”

Section: Introductionmentioning

confidence: 99%

Effects of Reishimmune-S, a Fungal Immunomodulatory Peptide Supplement, on the Quality of Life and Circulating Natural Killer Cell Profiles of Patients With Early Breast Cancer Receiving Adjuvant Endocrine Therapy

Su,

Huang,

Lin

et al. 2024

Integr Cancer Ther

View full text Add to dashboard Cite

Objectives: To evaluate the effects of Reishimmune-S, a fungal immunomodulatory peptide, on the quality of life (QoL) and natural killer (NK) cell subpopulations in patients receiving adjuvant endocrine therapy (ET) for breast cancer (BC). Methods: Patients who received adjuvant ET for stage I-III hormone receptor-positive BC without active infection were enrolled in this prospective pilot study. Reishimmune-S was administered sublingually daily for 6 months. QoL scores, circulating immune cell levels, including lymphocyte/NK cell subpopulations, and plasma levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-α were measured at baseline and every 4 weeks. Data were analyzed using linear mixed-effect regression models. Results: Nineteen participants were included in the analyses. One patient with underlying asthma did not complete the study owing to the occurrence of skin rashes 15 days after the initiation of Reishimmune-S. No other adverse events were reported. Reishimmune-S supplementation significantly improved the cognitive function at 3 months and significantly decreased the fatigue and insomnia levels at 3 and 6 months, respectively. There was no significant change in the global health/QoL score between baseline and week 4 of treatment. The proportion of CD19+ lymphocytes was significantly higher at 3 and 6 months, and that of NKG2A+ and NKp30+ NK cells was significantly lower at 6 months than at baseline. In addition, fatigue positively correlated with the proportion of NKp30+ NK cells (β ± standard error: 24.48 ± 8.75, P = .007 in the mixed-effect model). Conclusions: Short-term supplementation with Reishimmune-S affected the circulating immune cell composition and exerted positive effects on cognitive function, fatigue, and insomnia in patients with BC undergoing adjuvant ET, providing a potential approach for the management of treatment-related adverse reactions in this patient population.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Reishimmune-S, a Fungal Immunomodulatory Peptide Supplement, on the Quality of Life and Circulating Natural Killer Cell Profiles of Patients With Early Breast Cancer Receiving Adjuvant Endocrine Therapy

Su,

Huang,

Lin

et al. 2024

Integr Cancer Ther

View full text Add to dashboard Cite

show abstract

Managing the Impact of Hormone Therapy

Kechagioglou,

Fuller-Shavel

2023

Integrative Oncology in Breast Cancer Care

View full text Add to dashboard Cite

The role of aromatase inhibitors in slim women with breast cancer-related lymphoedema: a reflective case series

Anvar

2023

Br J Community Nurs

View full text Add to dashboard Cite

Background: This case series follows the reflective processes undertaken, when five slim women presented with reactive oedemas of the forearm and hand, that did not respond to usual therapy. Aim: To raise awareness about Aromatase Inhibitor (AI), Letrozole. Methods: Possible causes, including Cyclin-Dependent Kinase 4 and 6 (CDK4/6) inhibitors, Ribociclib and Axillary Web Syndrome, were explored and reviewed, and potential effective treatment options were then sought. New cases presented, which discounted each theory, until Letrozole was suspected. Results: Inflammatory oedemas were explained by the mechanisms-of-action relating to Aromatase Inhibitor Associated Musculoskeletal Syndrome (AIMSS), the severity of which, especially for slim women with oestrogen deprivation, causes almost 50% of women to cease treatment within 6 months; risking disease reoccurrence. Conclusion: Permissions were gained, a table was collated and sent to referring consultants, requesting risk/benefit analysis of Letrozole with a medication review. If non-responsive, inflammatory oedemas present in clinic, AIs should be considered as a trigger.

show abstract

Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer

Cited by 3 publications

References 73 publications

Effects of Reishimmune-S, a Fungal Immunomodulatory Peptide Supplement, on the Quality of Life and Circulating Natural Killer Cell Profiles of Patients With Early Breast Cancer Receiving Adjuvant Endocrine Therapy

Effects of Reishimmune-S, a Fungal Immunomodulatory Peptide Supplement, on the Quality of Life and Circulating Natural Killer Cell Profiles of Patients With Early Breast Cancer Receiving Adjuvant Endocrine Therapy

Managing the Impact of Hormone Therapy

The role of aromatase inhibitors in slim women with breast cancer-related lymphoedema: a reflective case series

Contact Info

Product

Resources

About